1
A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:May 3, 2023Active, not recruiting
Refractory Multiple Myeloma: 1466 Clinical Trials, Page 1 of 147
Hide Studies Not Open or Pending
2
CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma
Condition(s):Relapsed/Refractory Multiple Myeloma(MM)Last Updated:September 24, 2021Terminated
3
Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:December 11, 2019Unknown status
4
Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma
Condition(s):Relapsed Multiple Myeloma; Refractory Multiple MyelomaLast Updated:May 4, 2022Withdrawn
5
Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM)
Condition(s):Relapsed and Refractory Multiple MyelomaLast Updated:February 5, 2021Completed
6
RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma
Condition(s):Relapsed, Refractory Multiple MyelomaLast Updated:January 14, 2022Recruiting
7
A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:September 27, 2022Withdrawn
8
Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:March 16, 2022Completed
9
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:May 19, 2023Not yet recruiting
10
Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:October 17, 2022Recruiting